Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 8/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2573505 | 0.91 | PARP1 (0.40) | MTORATRCNR1RAB9ACNR2 | |
| SCHEMBL2570302 | 0.89 | MTOR (0.44) | MTORCNR1KCNH2SLC16A3SLC16A1 | |
| Hydrochloric Acid SCHEMBL2573524 | 0.88 | MTOR (0.43) | MTORCNR1KCNH2SLC16A3SLC16A1 | |
| SCHEMBL2569696 | 0.88 | MTOR (0.43) | MTORCNR1SLC16A3SLC16A1CNR2 | |
| SCHEMBL2573394 | 0.86 | CNR2 (0.40) | MTORCNR1KCNH2SLC16A3SLC16A1 | |
| SCHEMBL2568616 | 0.86 | CNR1 (0.40) | MTORCNR1KCNH2RAB9ACNR2 | |
| SCHEMBL2571582 | 0.84 | MTOR (0.43) | MTORCNR1CNR2FYNCECR2 | |
| SCHEMBL2570356 | 0.84 | KDM1A (0.39) | CNR1CNR2FYNCECR2 | |
| Hydrochloric Acid SCHEMBL2574144 | 0.84 | MTOR (0.42) | MTORCNR1KCNH2CNR2FYN | |
| SCHEMBL2572048 | 0.83 | NR5A2 (0.42) | CNR1RAB9ASLC16A3SLC16A1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8273738-B2 | Imidazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2090570-B1 | IMIDAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-2090570-A1 | IMIDAZOLE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | MTOR 1051/4885ATR 2476/4885CNR1 1/4885 |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | MTOR 1051/4885ATR 2476/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.